On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value

RPRX

<p>有望在 2030 年前實現 47 億美元或更多的投資組合收益，顯著高於共識目標，預計在未來 5 年內實現至少中位數的年均總股東回報率，並且有望因對 Royalty Pharma 平台價值的認可而獲得顯著的上行潛力</p>

Royalty Pharma 投資者日突顯了公司強勁的增長前景及其推動價值創造的計劃